CANCER AND LEUKEMIA GROUP B

癌症和白血病 B 组

• 批准号: 2390612
• 负责人: STEPHEN R SEAGREN
• 金额: $ 28.59万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-04-01 至 1998-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2390612
• 关键词: T cell receptor; acute lymphocytic leukemia; antineoplastics; breast neoplasms; cancer prevention; cis platinum compound; clinical trials; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; etoposide; gene rearrangement; human subject; human therapy evaluation; hydrazines; ifosfamide; lung neoplasms; lymphocytic leukemia; lymphoma; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; nucleoside analog; placebos; prednisone; smoking cessation; vincristine

This application seeks support for the activities of CALGB investigators, participating through the University of California San Diego School of Medicine and adjunct institutions, in the programs of the Cancer and Leukemia Group B. During the coming grant period, we will continue to make major contributions to group accrual, Group science, and group administration. We project a modest increase in accrual over the 5 year upcoming grant cycle based on enhanced activities both at the main member institution and in our adjuncts, with a minimum goal of 250 accrued cases in the first year of this application. We expect women to be approximately 50% of all patients we accrue to clinical trials. Increased emphasis will be placed on accruing minorities to CALGB studies. We expect to continue to contribute extensively to the intellectual productivity of the Group by designing and chairing protocols, presenting pilot observations for Group validation and expansion, and by stimulating more basic research components to Group activities. We plan to continue direct service to the group by developing one or more reference laboratories for new CALGB correlative science projects in lung cancer. Members of our institution expect to continue their major contributions to Group science/administration as committee chairs (Seagren - Radiation Modality Committee; Green - Respiratory Committee), Core Committee members, or members of standing Group scientific and administrative committees. We will continue to serve as a clinical resource and research base for CCOP activities of our CCOP adjunct in Las Vegas, Nevada, and at Kaiser CCOP San Diego and are working to further strengthen our clinical trials Outreach Network as a means to both assure accrual and stimulate and strengthen the intellectual vitality and state-of-the-art quality of overall oncology care delivered in the entire San Diego area. Ongoing participation in CALGB continues to serve as an important educational vehicle for Faculty, Fellows, and House staff at UCSD, the Veterans Administration Medical Center, the Naval Regional Medical Center, Santa Barbara, Hoag and Scripps Clinic and Research Foundation as well as for all the affiliated participants in private practice of hematology and medical oncology who share in our CALGB activities.

本申请寻求对 CALGB 研究人员活动的支持， 通过加州大学圣地亚哥分校参与 癌症和癌症计划中的医学和附属机构 B 类白血病。在接下来的资助期内，我们将继续 对团体应计、团体科学和团体做出重大贡献 行政。 我们预计未来 5 年应计费用将小幅增加 即将到来的赠款周期基于主要成员的增强活动 机构和我们的附属机构，至少目标是 250 个应计案件 在本申请的第一年。 我们期望女性成为 我们招募的所有患者中约有 50% 接受了临床试验。 将更加重视吸引少数族裔加入 CALGB 研究。我们期望继续为该领域做出广泛贡献 通过设计和主持提高集团的智力生产力 协议，提出试点观察结果以供小组验证和 扩展，并通过刺激更多的基础研究组成部分 活动。 我们计划继续为该集团提供直接服务 为新的 CALGB 相关性开发一个或多个参考实验室 肺癌的科学项目。 我们机构的成员期望 继续为集团科学/管理做出重大贡献 委员会主席（Seagren - 辐射方式委员会；绿色 - 呼吸委员会）、核心委员会成员或常务成员 集团科学和行政委员会。 我们将继续 作为我们的 CCOP 活动的临床资源和研究基地 在内华达州拉斯维加斯和圣地亚哥 Kaiser CCOP 担任 CCOP 兼职人员 致力于进一步加强我们的临床试验外展网络作为 意味着既确保应计收益又刺激和加强 整体肿瘤学的智力活力和最先进的质量 在整个圣地亚哥地区提供护理。 持续参与 CALGB 继续作为教师的重要教育工具， 加州大学圣地亚哥分校、退伍军人管理局医疗中心的研究员和内部工作人员 中心、海军地区医疗中心、圣巴巴拉、霍格和 斯克里普斯诊所和研究基金会以及所有附属机构 血液学和肿瘤内科私人执业的参与者 参与我们的 CALGB 活动。